Neuren Pharmaceuticals Ltd (ASX: NEU) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Neuren Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.98 billion
P/E Ratio 36.90
Dividend Yield 0.00%
Shares Outstanding 128.97 million
Earnings per share 0.436
Dividend per share N/A
Year To Date Return 102.64%
Earnings Yield 2.71%
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Neuren Pharmaceuticals Ltd (ASX: NEU)
    Latest News

    a tired and sad looking bulldog sits at an office desk with a pen an paper on it and a cup of coffee with his head resting on the desk as he gives a mournful look to the camera.
    Share Market News

    Here are the top 10 ASX 200 shares today

    Do you own any of today's winning ASX 200 shares?

    Read more »

    a man looks down at his phone with a look of happy surprise on his face as though he is thrilled with good news.
    Share Gainers

    These were the best performers on the ASX 200 in November

    These ASX 200 shares made their shareholders smile last month.

    Read more »

    A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
    Healthcare Shares

    Buy this ASX 200 stock for big returns after 'impressive launch'

    Bell Potter is feeling very bullish about this pharma stock.

    Read more »

    Man in a wheelchair at a desk, checking his computer.
    Share Market News

    5 things to watch on the ASX 200 on Monday

    The ASX 200 looks set to start the week on a positive note.

    Read more »

    a woman struggles to hold a large pile of folders and documents with only her eyes appearing over the top of the pile.
    Share Market News

    Here's how the ASX 200 market sectors stacked up this week

    The ASX 200 fell by 0.02% this week, but healthcare stocks lived up to their name.

    Read more »

    A group of young friends are supposed to be having a rooftop party but the lights have dimmed, the energy is low, and it's a bit of a downer.
    Share Market News

    Here are the top 10 ASX 200 shares today

    Do you own any of today's few winners?

    Read more »

    A couple working on a laptop laugh as they discuss their ASX share portfolio.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was a strong start to the week's trading this Monday.

    Read more »

    A young boy wearing a hat, sunnies and striped singlet looks fierce and flexes his arm in victory.
    Share Market News

    Here are the top 10 ASX 200 shares today

    Do you own any of today's winning shares?

    Read more »

    A man clenches his fists in excitement as gold coins fall from the sky.
    Share Gainers

    Why Block, Core Lithium, Neuren, and Tietto shares are charging higher

    These ASX shares are ending the week in style. But why?

    Read more »

    A neon sign says 'Top Ten'.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was a happy day of share market rises for the ASX this Tuesday.

    Read more »

    A senior couple discusses a share trade they are making on a laptop computer
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was another horror show on the ASX 200 today.

    Read more »

    A coal miner wearing a red hard hat holds a piece of coal up and gives the thumbs up sign in his other hand
    Share Gainers

    Here are the top 10 ASX 200 shares today

    The ASX 200 had a happy hump day this Wednesday.

    Read more »

    Frequently Asked Questions

    No, Neuren Pharmaceuticals does not pay dividends at this time. 

    Neuren Pharmaceuticals Limited (ASX: NEU) listed on the ASX on 3 February 2005.

    NEU ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Neuren Pharmaceuticals Ltd

    Neuren Pharmaceuticals Limited (ASX: NEU) is a biopharmaceutical company specialising in developing new therapies for neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells. 

    In March 2023, the US Food and Drug Administration approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adults and children two years and older. Neuren's US partner Acadia Pharmaceuticals (NASDAQ: ACAD) holds a worldwide exclusive licence from Neuren for trofinetide. At this time, DAYBUE is the first and only drug approved for the treatment of Rett syndrome. Trofinetide has also demonstrated clinical benefit in a Phase 2 trial in treating Fragile X syndrome.

    Neuren's second product NNZ-2591 is currently in Phase 2 clinical trials for the treatment of Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome, and Prader-Willi syndrome. The drug candidate has shown positive effects in mouse models of each syndrome and was successful in a Phase 1 clinical trial. The number of patients across these four disorders is estimated as five times the number of Rett syndrome patients. There are currently no drugs approved for these conditions, apart from growth hormone to treat some aspects of Prader-Willi. 

    Acadia Pharmaceuticals also holds a worldwide exclusive licence to develop and commercialise NNZ-2591 for Rett syndrome and Fragile X syndrome. Neuren retains worldwide rights to NNZ-2591 in all other indications.

    NEU Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    05 Dec 2023 $15.66 $-0.45 -2.79% 450,168 $16.07 $16.11 $15.63
    04 Dec 2023 $16.11 $0.02 0.12% 557,542 $16.30 $16.40 $16.11
    01 Dec 2023 $16.09 $0.59 3.81% 541,231 $15.61 $16.26 $15.60
    30 Nov 2023 $15.50 $0.46 3.06% 866,121 $14.95 $15.50 $14.82
    29 Nov 2023 $15.04 $-0.11 -0.73% 325,279 $15.20 $15.29 $15.01
    28 Nov 2023 $15.15 $0.29 1.95% 745,247 $15.10 $15.30 $14.93
    27 Nov 2023 $14.86 $-0.04 -0.27% 199,665 $15.00 $15.14 $14.84
    24 Nov 2023 $14.90 $0.06 0.40% 421,433 $15.00 $15.16 $14.83
    23 Nov 2023 $14.84 $-0.27 -1.79% 291,930 $15.11 $15.11 $14.81
    22 Nov 2023 $15.11 $-0.04 -0.26% 597,036 $15.10 $15.29 $15.00
    21 Nov 2023 $15.15 $0.39 2.64% 469,799 $14.90 $15.39 $14.84
    20 Nov 2023 $14.76 $0.08 0.54% 908,334 $15.50 $15.53 $14.74
    17 Nov 2023 $14.68 $-0.14 -0.94% 593,625 $14.99 $15.02 $14.68
    16 Nov 2023 $14.82 $0.04 0.27% 900,138 $14.89 $15.30 $14.63
    15 Nov 2023 $14.78 $0.60 4.23% 533,105 $14.49 $14.98 $14.29
    14 Nov 2023 $14.18 $-0.15 -1.05% 585,362 $14.54 $14.70 $14.16
    13 Nov 2023 $14.33 $-0.13 -0.90% 783,875 $14.48 $14.90 $14.01
    10 Nov 2023 $14.46 $1.32 10.05% 797,276 $13.05 $14.55 $13.05
    09 Nov 2023 $13.14 $0.23 1.78% 857,379 $12.96 $13.55 $12.93
    08 Nov 2023 $12.91 $0.16 1.25% 463,266 $12.75 $13.00 $12.73
    07 Nov 2023 $12.75 $-0.03 -0.23% 545,709 $12.52 $12.85 $12.45

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    13 Sep 2023 Joseph(Joe) Basile Buy 5,000 $59,950
    On-market trade.
    14 Jun 2023 Trevor Scott Sell 1,175,000 $15,275,000
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Trevor D Scott Non-Executive Director Mar 2002
    Trevor joined the Neuren Board in 2002. He is the founder of T.D. Scott and Co., an accountancy and consulting firm, which he formed in 1988. He is an experienced advisor to companies across a variety of industries. Trevor serves on numerous corporate boards and is chairman of several.
    Ms Dianne Margaret Angus Non-Executive Director Jul 2018
    Dianne joined the Neuren Board in 2018. She has worked as a senior executive and non-executive director within
    the biotechnology, biopharmaceutical and agritech industries for over twenty-five years. She has created numerous
    global industry partnerships which include Prana Biotechnology, Gerolymatos International, Florigene, Suntory &
    Monsanto to yield novel and competitive medical, pharmaceutical and agricultural products. Dianne has successfully
    forged strong partnerships with key medical opinion leaders to create innovative clinical research programs and
    driven the development path for novel neurological pre-clinical agents to late-stage clinical assets before the FDA
    and European regulators. With over fifteen years experience in an ASX and NASDAQ listed company, she has expertise
    in business development, capital raising, investor relations, regulatory affairs and intellectual property, together
    with corporate governance and compliance capabilities. Dianne holds a Masters degree in biotechnology and is a
    registered patent attorney.
    Mr Jonathan (Jon) Charles Pilcher Chief Executive OfficerManaging Director Aug 2013
    Jon joined Neuren in 2013 as CFO and was appointed CEO in May 2020. He has played a central role in all aspects of Neuren s R&D, commercial and corporate activities. Before joining Neuren he was a member of the leadership team at Acrux (ASX: ACR) throughout a period that included Acruxs IPO and listing on the ASX, the development and FDA approval of three novel pharmaceutical products and a transforming licensing deal with Eli Lilly in 2010. He formerly spent seven years in a series of executive positions in the R&D and corporate functions of international pharmaceutical groups Medeva and Celltech, which are now part of UCB. Jon is a Chartered Accountant and holds a degree in Biotechnology from the University of Reading in the UK. He is a non executive director of BTC Health Limited (ASX: BTC).
    Dr Jenny Lee Harry Non-Executive Director Jul 2018
    Jenny joined the Neuren Board in 2018. She has 20 years experience in executive management of companies in the
    biotechnology and biopharmaceutical industry. Jenny is an accomplished CEO and Managing Director with experience
    in growing companies from start up to commercialisation. She has served on Boards of a number of listed and unlisted
    companies and is currently a Non Executive Director of Aeris Environmental Limited (ASX:AEI) and on the Boards IP
    sub-committee of the Childrens Medical Research Institute. Jenny is a graduate of the Harvard Business School General
    Manager Program and the Australian Institute of Company Directors.
    Mr Patrick Davies Non-Executive DirectorNon-Executive Chairman Jul 2018
    Patrick joined the Neuren Board in 2018. He has held executive management roles in the Australian and New Zealand healthcare industry for over twenty five years having performed successfully in senior roles across many industry sectors including pharmacy, primary care, pharmaceutical and consumer products. During his ten year period as Chief Executive Officer of EBOS Group Limited (and previously Symbion), the enterprise value of the group achieved compound annual growth in enterprise value of +20% (from circa $450M to in excess of $3.1B). He is a director on other corporate boards and provides strategic advice to a range of healthcare businesses and investors.
    Mr Joseph(Joe) Basile Non-Executive Director Mar 2023
    Mr Basile has held a number of executive roles in the pharmaceutical industry for over 30 years, most recently as Group CFO at iNova Pharmaceuticals based in Singapore and prior to that with Novartis in senior Finance leadership and Commercial Sales leadership roles in Australia and Asia. Joe has experience in corporate mergers and acquisitions, capital management and overseeing expansion activities .
    Ms Lauren Frazer Chief Financial OfficerCompany Secretary Aug 2020
    Lauren Frazer Chief Financial OfficerCompany Secretary
    LIZA SQUIRES, M.D. Chief Medical Officer
    LARRY GLASS Chief Science Officer
    VIRGINIE DUREZ Senior Director Product Development & Project Management

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    NATIONAL NOMINEES LIMITED 11,810,223 9.35%
    Citicorp Nominees Pty Limited 10,759,990 8.52%
    J P Morgan Nominees Australia Pty Limited 8,875,428 7.03%
    HSBC Custody Nominees (Australia) Limited A/C 2 6,639,176 5.26%
    Cameron Richard Pty Ltd 4,206,313 3.33%
    BNP Paribas Noms Pty Ltd 2,710,864 2.15%
    Stuart Andrew Pty Ltd 2,460,000 1.95%
    Essex Castle Limited 2,367,144 1.87%
    Smithley Super Pty Ltd 2,010,000 1.59%
    Linwierik Super Pty Ltd 1,885,000 1.49%
    Sharesies Nominee Limited 1,385,966 1.10%
    Mxb Investments Llc 1,330,000 1.05%
    Dr Trevor Scott 1,000,000 0.79%
    First Colbyco Pty Ltd 790,000 0.63%
    Mjhft Pty Ltd 750,000 0.59%
    Dr Robin Lance Congreve 671,637 0.53%
    Hobson Wealth Custodians Ltd 589,337 0.47%
    Emancipayte Pty Ltd 476,607 0.38%
    Bnp Paribas Nominees Pty Ltd Acf Clearstream 465,450 0.37%